Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL GOLD

NPI
1073549176
CMS profile
48145
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$142,747.23

186 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL GOLD

NPI 1073549176 · CMS profile ID 48145

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073549176?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL GOLD, NPI 1073549176, CMS profile ID 48145. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073549176?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MICHAEL GOLD, NPI 1073549176, CMS profile ID 48145. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073549176?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MICHAEL GOLD, NPI 1073549176, CMS profile ID 48145, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1073549176?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

186 matching records · $142,747.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 186 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 186.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $3,560.0009/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047735 CMS
ABBVIE INC. $1,780.0009/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047737 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.6409/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887336065 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $10.4809/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947509441 CMS
GENZYME CORPORATION $25.2709/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938792905 CMS
E.R. Squibb & Sons, L.L.C. $26.4609/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932583653 CMS
Almirall LLC $16.9309/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965163221 CMS
Almirall LLC $55.6809/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965163223 CMS
Novartis Pharmaceuticals Corporation $22.3508/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893704267 CMS
PFIZER INC. $2.5308/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949566713 CMS
ABBVIE INC. $20.7408/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047733 CMS
Allergan, Inc. $149.8008/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889895837 CMS
Allergan, Inc. $33.3808/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889895833 CMS
Allergan, Inc. $1,290.5008/26/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889895835 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $13.2708/24/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947509433 CMS
Genentech USA, Inc. $18.9908/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950764561 CMS
ABBVIE INC. $21.7908/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047731 CMS
STRATA Skin Sciences, Inc. $775.0008/12/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964161702 CMS
Allergan, Inc. $2,225.0008/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889895831 CMS
Allergan, Inc. $43.9108/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889895829 CMS
Galderma Laboratories, L.P. $73.0108/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952273761 CMS
Solta Medical, a division of Bausch Health US, LLC $2,610.0008/02/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941783119 CMS
ABBVIE INC. $26.6208/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047729 CMS
MAYNE PHARMA INC. $15.6908/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959836339 CMS
Allergan, Inc. $13.7207/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889895827 CMS
ABBVIE INC. $17.4107/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047727 CMS
GENZYME CORPORATION $128.5807/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938792893 CMS
ABBVIE INC. $15.9707/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047725 CMS
ABBVIE INC. $24.3207/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047723 CMS
PFIZER INC. $21.1707/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949616357 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $20.5607/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947509431 CMS
Merz North America, Inc. $37.6907/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950342313 CMS
Merz North America, Inc. $466.5607/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950342311 CMS
Merz North America, Inc. $2,529.1907/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950342309 CMS
Merz North America, Inc. $132.2007/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950342315 CMS
Novartis Pharmaceuticals Corporation $12.5607/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893704256 CMS
Solta Medical, a division of Bausch Health US, LLC $2,610.0007/12/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941783111 CMS
PFIZER INC. $6.0507/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949607173 CMS
Lumenis BE (HK) Limited $1,025.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942794139 CMS
Solta Medical, a division of Bausch Health US, LLC $435.0006/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941783127 CMS
Novartis Pharmaceuticals Corporation $11.9306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893704253 CMS
PFIZER INC. $1.4306/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949636929 CMS
Solta Medical, a division of Bausch Health US, LLC $1,740.0006/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941783123 CMS
Solta Medical, a division of Bausch Health US, LLC $1,740.0006/23/2022 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941783143 CMS
ABBVIE INC. $24.7606/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047721 CMS
ABBVIE INC. $14.6406/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047719 CMS
ABBVIE INC. $6.9606/10/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047717 CMS
Allergan, Inc. $1,780.0006/09/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889895825 CMS
ABBVIE INC. $28,750.0006/07/2022 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891047715 CMS
Novartis Pharmaceuticals Corporation $12.5606/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893704249 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $95,167.23 173
PY2020 $45,648.59 140
PY2021 $73,507.08 145
PY2022 $142,747.23 186
PY2023 $92,846.45 162
PY2024 $125,018.09 190
PY2025 $173,271.46 206

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $373,719.62 46
PY2024 Recipient $1,007.07 3
PY2024 Principal investigator $326,767.50 36
PY2023 Principal investigator $698,835.45 48
PY2022 Principal investigator $1,057,457.10 60
PY2021 Principal investigator $1,412,059.53 70
PY2020 Principal investigator $415,542.55 44
PY2019 Recipient $27,312.89 6
PY2019 Principal investigator $430,298.83 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $916.68 12/31/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER LLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202534491
Principal investigator 1 ABBVIE INC. $31,356.26 12/31/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER LLC
A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation No dispute reported 06/30/2026 1202534493
Principal investigator 1 ABBVIE INC. $6,136.80 12/17/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202530992
Principal investigator 1 ABBVIE INC. $31,128.10 12/17/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202530994
Principal investigator 1 Incyte Corporation $2,173.00 12/05/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598157
Principal investigator 1 Incyte Corporation $1,841.00 11/19/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598136
Principal investigator 1 Incyte Corporation $1,459.50 11/19/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598139
Principal investigator 1 Incyte Corporation $44.00 11/19/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598160
Principal investigator 1 Incyte Corporation $44.00 11/19/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598164
Principal investigator 1 ABBVIE INC. $4,528.20 11/13/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202524149
Principal investigator 1 ABBVIE INC. $11,203.11 11/13/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202524183
Principal investigator 1 ABBVIE INC. $8,137.50 11/07/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202523581
Principal investigator 1 ABBVIE INC. $3,513.60 11/04/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202520569
Principal investigator 1 ABBVIE INC. $10,553.40 10/15/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202516859
Principal investigator 1 Incyte Corporation $74.00 10/09/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598129
Principal investigator 1 Incyte Corporation $1,947.00 10/09/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598132
Principal investigator 1 Incyte Corporation $2,800.00 10/09/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598143
Principal investigator 1 Incyte Corporation $745.00 10/09/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598148
Principal investigator 1 Incyte Corporation $1,775.00 10/09/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598153
Principal investigator 1 Incyte Corporation $44.00 10/09/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598168
Principal investigator 1 Incyte Corporation $44.00 10/09/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598172
Principal investigator 1 Incyte Corporation $1,841.00 10/09/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598176
Principal investigator 1 ABBVIE INC. $3,513.60 10/02/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202513047
Principal investigator 1 ABBVIE INC. $12,050.40 09/18/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202511566
Principal investigator 1 Incyte Corporation $44.00 09/12/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598105
Principal investigator 1 Incyte Corporation $74.00 09/12/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598108
Principal investigator 1 Incyte Corporation $2,033.50 09/12/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598111
Principal investigator 1 Incyte Corporation $1,947.00 09/12/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598118
Principal investigator 1 Incyte Corporation $2,800.00 09/12/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598120
Principal investigator 1 ABBVIE INC. $16,541.40 08/14/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504903
Principal investigator 1 Incyte Corporation $10,000.00 08/14/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598101
Principal investigator 1 Incyte Corporation $750.00 08/14/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240598114
Principal investigator 1 ABBVIE INC. $19,617.00 07/16/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202498338
Principal investigator 1 ABBVIE INC. $16,667.40 06/12/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202491189
Principal investigator 1 ABBVIE INC. $21,366.00 05/16/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202485341
Principal investigator 1 UCB SA $197.78 04/28/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246659450
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,910.00 04/18/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223278490
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 04/18/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223278492
Principal investigator 1 ABBVIE INC. $22,944.60 04/16/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202476851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 04/16/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223278132
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 04/16/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223278134
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 04/16/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223278136
Principal investigator 1 ABBVIE INC. $21,996.60 03/13/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202463115
Principal investigator 1 ABBVIE INC. $18,891.60 02/13/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202450942
Principal investigator 1 ABBVIE INC. $29,257.32 01/16/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202439083
Principal investigator 1 UCB SA $43,012.27 01/03/2025 Non-covered Recipient Entity
TENNESSEE CLINICAL RESEARCH CENTER
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246657518

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2022 Amount invested $0.00 1
PY2022 Value of interest $1,264.85 1
PY2021 Amount invested $2,405.00 1
PY2021 Value of interest $2,107.06 1
PY2020 Amount invested $2,405.00 1
PY2020 Value of interest $2,030.16 1
PY2019 Amount invested $2,405.00 1
PY2019 Value of interest $1,784.08 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2019–2022

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2022 Medimetriks Pharmaceuticals, Inc. $0.00 $1,264.85 Dr. Gold has 1,538 shares at $0.8224 per share. Cert.# (s) 124. Physician Covered Recipient No dispute reported 06/30/2026 885344965
PY2021 Medimetriks Pharmaceuticals, Inc. $2,405.00 $2,107.06 HCP owns 1538 shares Physician Covered Recipient No dispute reported 06/30/2026 803534827
PY2020 Medimetriks Pharmaceuticals, Inc. $2,405.00 $2,030.16 Shares of Stock Physician Covered Recipient No dispute reported 06/30/2026 746592327
PY2019 Medimetriks Pharmaceuticals, Inc. $2,405.00 $1,784.08 Shares of Stock Physician Covered Recipient No dispute reported 06/30/2026 703279847